Analyst actions: MDT Buy target raised; SNN rating changes; GSK plan disclosed
Analyst updates: MDT maintained Buy and raised price target to $110; SNN Hold and coverage notes; GSK Underweight downgrade. Separately, GSK plans a September Phase 3 mRNA flu trial.